Cardiac structure and function and arterial circulation in hypertensive patients with and without metabolic syndrome

Journal of Human Hypertension

Volumn 21, Issue 9, 2007, Pages 729-735

  Ferrara, L A ^a   Guida, L ^a   Ferrara, F ^a   De Luca, G ^a   Staiano, L ^a   Celentano, A ^a   Mancini, M ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIHYPERTENSIVE AGENT;

ADULT; ANKLE BRACHIAL INDEX; ANTIHYPERTENSIVE THERAPY; ARTERIAL CIRCULATION; ARTERY INTIMA PROLIFERATION; ARTERY MEDIA; ARTICLE; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE MONITORING; CAROTID ARTERY; CONTROLLED STUDY; DOPPLER ECHOCARDIOGRAPHY; ECHOGRAPHY; FEMALE; HEART ATRIUM ENLARGEMENT; HEART FUNCTION; HEART LEFT VENTRICLE FILLING PRESSURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; LABORATORY TEST; M MODE ECHOCARDIOGRAPHY; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; OUTPATIENT CARE; PHYSICAL EXAMINATION; PREVALENCE;

ADULT; FEMALE; HEART; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; METABOLIC SYNDROME X; MIDDLE AGED; MYOCARDIUM; VENTRICULAR FUNCTION, LEFT;

EID: 34548320856     PISSN: 09509240     EISSN: 14765527     Source Type: Journal    
DOI: 10.1038/sj.jhh.1002222     Document Type: Article

References (40)

1. Reaven GM. Syndrome X: 6 years later. J Intern Med 1994; 236 Suppl 736): 13-22.
2. Kesaniemi YA, Lilja M, Kervinen K, Rantala. A. Multiple metabolic syndrome: Aspects of genetic epidemiology and molecular genetics. Ann Med 1992; 24: 461-464.
3. Schmidt MI, Duncan BB, Watson RL, Sharrett AR, Brancati FL, Heiss G. A metabolic syndrome in whites and African-Americans. The Atherosclerosis Risk in Communities baseline study. Diabetes Care 1996; 19: 414-418.
4. Kaplan NM. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia and hypertension. Arch Intern Med 1989; 149: 1514-1520.
5. World Health Organization. Definition, Diagnosis, and Classification of Diabetes Mellitus and Its Complications: Report of a WHO Consultation WHO: Geneva, 1999.
6. Mitka M. Does the metabolic syndrome really exist? Diabetes and heart disease groups spar over issue. JAMA 2005; 294: 2010-2013.
7. Executive Summary. The third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults (Adult treatment Panel III). JAMA 2001; 285: 2486-2497.
8. Balkau B, Charles MA, Drivsholm. T, Borch-Johnsen K, Wareham N, Yudkin JS, et al., European Group For The Study Of Insulin Resistance (EGIR). Frequency of the WHO metabolic syndrome in European cohorts, and an alternative definition of an insulin resistance syndrome. Diabetes Metab 2002; 28: 364-376.
9. Einhorn D, Reaven GM, Cobin RH, Ford E, Ganda OP, Handelsman Y et al. American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003; 9: 237-252.
10. Alberti KG, Zimmet P, Shaw J, IDF Epidemiology Task Force Consensus Group. The metabolic syndrome - a new worldwide definition. Lancet 2005; 366: 1059-1062.
11. Ferrara LA, Guida L, Pasanisi F, Celentano A, Palmieri V, Iannuzzi R et al. Isolated office hypertension and end organ damage. J Hypertens 1997; 15: 979-985.
12. Friedewald WT, Lery RI, Fredrickson DS. Estimation of plasma low density lipoprotein cholesterol concentration without use of the preparative ultracentrifuge. Clin Chem 1972; 18: 499-502.
13. Sahn DJ, De Maria A, Kisslo J, Weyman A. The Committee on M-mode standardization of the American Society of Echocardiography: recommendations regarding quantitation in M-mode echocardiography: results of a survey of echocardiographic measurements. Circulation 1978; 58: 1072-1083.
14. Devereux RB, Reichek N. Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977; 55: 613-618.
15. Ferrara LA, Vaccaro O, Cardoni O, Laurenzi M, Mancini M, Zanchetti A. Indexation criteria of ventricular mass and predictive role of blood pressure and body composition. Am J Hypertens 2005; 18: 1282-1287.
16. Devereux RB, Dahlof B, Levy D, Pfeffer MA. Comparison of enalapril versus nifedipine to decrease left ventricular hypertrophy in systemic hypertension (the PRESERVE trial). Am J Cardiol 1996; 78: 61-65.
17. de Simone G, Daniels SR, Devereux RB, Meyer RA, Roman MJ, de Divitiis O et al. Left ventricular mass and body size in normotensive children and adults: Assessment of allometric relations and impact of overweight. J Am Coll Cardiol 1992; 20: 1251-1260.
18. Teichholz LE, Kreulen T, Herman MV, Gorlin R. Problems in echocardiographic volume determinations: Echocardiographic-angiographic correlations in the presence or absence of asinergy. Am J Cardiol 1976; 37: 7-11.
19. Wallerson DC, Ganau A, Roman MJ, Devereux RB. Measurements of cardiac output by M-mode and two dimensional echocardiography: Application to patients with hypertension. Eur Heart J 1990; 11(Suppl 1): 67-78.
20. Kuo LC, Quinones MA, Rokey R, Sartori M, Abinader EG, Zoghbi WA. Quantification of atrial contribution to left ventricular filling by pulsed Doppler echocardiography and the effect of age in normal and diseased hearts. Am J Cardiol 1987; 59: 1174-1178.
21. Bond MG, Wilmoth SK, Enevold GL, Strickland HL. Detection and monitoring of asymptomatic atherosclerosis in clinical trials. Am J Med 1989; 86(Suppl 4A): 33-36.
22. Pignoli P, Tremoli E, Poli A, Oreste P, Paoletti R. Intimal plus medial thickness of the arterial wall: A direct measurement with ultrasound imaging. Circulation 1986; 74: 1399-1406.
23. Ferrara LA, Mancini M, Celentano A, Galderisi M, Iannuzzi R, Marotta T et al. Early changes of the arterial carotid wall in uncomplicated primary hypertensive patients. Study by ultrasound high-resolution B-mode imaging. Arterioscl Thromb 1994; 14: 1290-1296.
24. Cuspidi C, Meani S, Fusi V, Severgnini B, Valerio C, Catini E et al. Metabolic syndrome and target organ damage in untreated essential hypertensives. J Hypertens 2004; 22: 1991-1998.
25. Ferrara LA, Vaccaro O, Cardoni O, Mancini M, Zanchetti A. Metabolic syndrome and left ventricular mass in the Gubbio Population Study. J Hypertens 2005; 23(Suppl 2): S133.
26. Kahn R, Buse J, Ferrannini E, Stern M, American Diabetes Association; European Association for the Study of Diabetes. The metabolia syndrome time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of.Diabetes. Diabetes Care 2005; 28: 2289-2304.
27. Eckel RH, Grundy SM, Zimmet PZ. The metabolic syndrome. Lancet 2005; 365: 1415-1428.
28. Chinali M, Devereux RB, Howard BV, Roman MJ, Bella JN, Liu JE et al. Comparison of cardiac structure and function in American Indians with and without the metabolic syndrome (the Strong Heart Study). Am J Cardiol 2004; 93: 40-44.
29. Cuspidi C, Meani S, Valerio C, Fusi V, Catini E, Sala C et al. Ambulatory blood pressure, target organ damage and left atrial size in never-treated essential hypertensive individuals. J Hypertens 2005; 23: 1589-1595.
30. Guida L, Celentano A, Iannuzzi R, Ferrara LA. Insulin resistance, ventricular mass and function in normoglycaemic hypertensives. Nutr Metab Cardiovasc Dis 2001; 11: 306-311.
31. Grandi AM, Piantanida E, Franzetti I, Bernasconi M, Maresca A, Marnini P et al. Effect of glycemic control on left ventricular diastolic function in type 1 diabetes mellitus. Am J Cardiol 2006; 97: 71-76.
32. Devereux RB, de Simone G, Pickering TG, Schwartz JE, Roman MJ. Relation of left ventricular midwall function to cardiovascular risk factors and arterial structure and function. Hypertension 1998; 31: 929-936.
33. Burchfiel CM, Skelton TN, Andrew ME, Garrison RJ, Arnett DK, Jones DW et al. Metabolic syndrome and echocardiographic left ventricular mass in blacks: The Atherosclerosis Risk in Communities (ARIC) Study. Circulation 2005; 112: 819-827.
34. Gariepy J, Massonneau M, Levenson J, Heudes D, Simon A. Evidence for in vivo carotid and femoral wall thickening in human hypertension. Groupe de Prevention Cardio-vasculaire en Medecine du Travail. Hypertension 1993; 22: 111-118.
35. Su TC, Lee YT, Chou S, Chen, GF, Wang JD, Twenty four hour ambulatory blood pressure and duration of hypertension as major determinants for intima-media thickness and atherosclerosis of carotid arteries. Atherosclerosis 2006; 184: 151-156.
36. Zakopoulos NA, Tsivgoulis G, Barlas G, Papamichael C, Spengos K, Manios E et al. Time rate of blood pressure variation is associated with increased common carotid artery intima-media thickness. Hypertension 2005; 45: 505-512.
37. Kawamoto R, Tomita H, Oka Y, Ohtsuka N, Kamitani A. MetaboAc syndrome and carotid atherosclerosis: Role of elevated blood pressure. J Atheroscler Thromb 2005; 12: 268-275.
38. Ferrara LA, Mancini M, Iannuzzi R, Marotta T, Gaeta I, Pasanisi F et al. Carotid diameter and blood flow velocities in cerebral circulation in hypertensive patients. Stroke 1995; 26: 418-421.
39. Olijhoek JK, van der Graaf Y, Banga JD, Algra A, Rabelink TJ, Visseren FL, the SMART Study Group. The metabolic syndrome is associated with advanced vascular damage in patients with coronary heart disease, stroke, peripheral arterial disease or abdominal aortic aneurysm. Eur Heart J 2004; 25: 342-348.
40. Costa LA, Canani LH, Lisboa HR, Tres GS, Gross JL. Aggregation of features of the metabolic syndrome is associated with increased prevalence of chronic complications in Type 2 diabetes. Diabet Med 2004; 21: 252-255.